tiprankstipranks
Advertisement
Advertisement

IMDX Stock Latest News

Insight Molecular Diagnostics Shareholders Back Board and Incentive Plan
Company AnnouncementsInsight Molecular Diagnostics Shareholders Back Board and Incentive Plan
10d ago
8K
IMDX
Insight Molecular Diagnostics Balances Progress and Cash Burn
PremiumCompany Announcements
Insight Molecular Diagnostics Balances Progress and Cash Burn
1M ago
IMDX
OncoCyte’s Earnings Call Maps Risky Path to Launch
PremiumCompany Announcements
OncoCyte’s Earnings Call Maps Risky Path to Launch
1M ago
IMDX
Insight Molecular Diagnostics Maintained at Buy as GraftAssure Platform Gains Traction; $9 Price Target Reaffirmed
PremiumRatings
Insight Molecular Diagnostics Maintained at Buy as GraftAssure Platform Gains Traction; $9 Price Target Reaffirmed
1M ago
IMDX
Insight Molecular Corrects Bylaws Disclosure in Annual Report
PremiumCompany Announcements
Insight Molecular Corrects Bylaws Disclosure in Annual Report
2M ago
8K
IMDX
Insight Molecular Diagnostics: Building Momentum with GraftAssure Platform and Favorable Risk‑Reward Supporting Buy Rating
PremiumRatingsInsight Molecular Diagnostics: Building Momentum with GraftAssure Platform and Favorable Risk‑Reward Supporting Buy Rating
2M ago
IMDX
OncoCyte Earnings Call: GraftAssureDx Drives Pivot
Premium
Company Announcements
OncoCyte Earnings Call: GraftAssureDx Drives Pivot
3M ago
IMDX
Buy Rating on IMDX Driven by Strong GraftAssure Traction, Upcoming FDA Catalyst, and Solid Balance Sheet
Premium
Ratings
Buy Rating on IMDX Driven by Strong GraftAssure Traction, Upcoming FDA Catalyst, and Solid Balance Sheet
3M ago
IMDX
Insight Molecular Diagnostics submits GraftAssureDx for FDA review
PremiumThe Fly
Insight Molecular Diagnostics submits GraftAssureDx for FDA review
3M ago
IMDX
Insight Molecular Diagnostics reports Q4 EPS (27c) vs. (28c) last year
PremiumThe Fly
Insight Molecular Diagnostics reports Q4 EPS (27c) vs. (28c) last year
3M ago
IMDX
OCX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
OCX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
3M ago
IMDX
Insight Molecular Diagnostics highlights publication of study on GraftAssure
PremiumThe Fly
Insight Molecular Diagnostics highlights publication of study on GraftAssure
4M ago
IMDX
Insight Molecular Diagnostics completes milestones advancing GraftAssureDx
PremiumThe FlyInsight Molecular Diagnostics completes milestones advancing GraftAssureDx
4M ago
IMDX
Insight Molecular Diagnostics: GraftAssureIQ Validation and Hospital Adoption Set Up 2026 as a Growth Inflection Year
Premium
Ratings
Insight Molecular Diagnostics: GraftAssureIQ Validation and Hospital Adoption Set Up 2026 as a Growth Inflection Year
4M ago
IMDX
Insight Molecular Diagnostics Signs Quest Specimen Collection Agreement
Premium
Company Announcements
Insight Molecular Diagnostics Signs Quest Specimen Collection Agreement
4M ago
8K
IMDX
Insight Molecular Diagnostics price target raised to $12 from $8 at Lake Street
PremiumThe Fly
Insight Molecular Diagnostics price target raised to $12 from $8 at Lake Street
4M ago
IMDX
Insight Molecular Diagnostics Raises Capital to Advance Transplant R&D
PremiumCompany Announcements
Insight Molecular Diagnostics Raises Capital to Advance Transplant R&D
4M ago
8K
IMDX
Insight Molecular Diagnostics Provides Updated Investor Presentation Materials
PremiumCompany Announcements
Insight Molecular Diagnostics Provides Updated Investor Presentation Materials
5M ago
8K
IMDX
Insight Molecular Diagnostics prices 4.53M shares at $5.75 in direct offering
PremiumThe Fly
Insight Molecular Diagnostics prices 4.53M shares at $5.75 in direct offering
5M ago
IMDX
Insight ‘congratulated’ STAR working group on organ health testing paper
PremiumThe FlyInsight ‘congratulated’ STAR working group on organ health testing paper
5M ago
IMDX
Insight Molecular Diagnostics appoints Nick Ioannou as VP, medical affairs
Premium
The Fly
Insight Molecular Diagnostics appoints Nick Ioannou as VP, medical affairs
6M ago
IMDX
Regulatory Momentum and Expanding Clinical Footprint Position Insight Molecular Diagnostics for a Pivotal 2026 Ramp
Premium
Ratings
Regulatory Momentum and Expanding Clinical Footprint Position Insight Molecular Diagnostics for a Pivotal 2026 Ramp
6M ago
IMDX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >